^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    OriC321

    i
    Associations
    News

    Trials

    Company:
    Zhejiang University
    Drug class:
    BCMA-targeted CAR-T immunotherapy, GPRC5D-targeted CAR-T immunotherapy
    Related drugs:
    Associations
    News

    Trials

    Apply
    A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma (NCT05325801)
    Phase 1
    Zhejiang University
    Not yet recruiting
    Last update posted :
    04/13/2022
    Initiation :
    04/01/2022
    Primary completion :
    03/01/2024
    Completion :
    03/01/2025
    GPRC5D
    |
    BM-ca • OriC321